Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880217 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 430
- Enrollment target
NCT00880217: Completed Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00880217 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 430 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (223% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00880217, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 430 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
Interventions
- DRUG Placebo
- DRUG Atomoxetine 80 mg/d
- DRUG OROS methylphenidate HCl 54 mg/d
- DRUG JNJ-31001074 3 mg/d
- DRUG JNJ-31001074 1 mg/d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00880217 record still lists
NCT00880217 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (223% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00880217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00880217 about?
NCT00880217 is a clinical study titled "A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
What is the current status of trial NCT00880217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 430 participants. The study started on 2009-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00880217?
The interventions under investigation include: Placebo (DRUG), Atomoxetine 80 mg/d (DRUG), OROS methylphenidate HCl 54 mg/d (DRUG), JNJ-31001074 3 mg/d (DRUG), JNJ-31001074 1 mg/d (DRUG).
Who is sponsoring clinical trial NCT00880217?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00880217's enrollment target sits among peer trials
430 90th of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia